This study aimed to evaluate serum IL-6 levels in plaque psoriasis patients and investigate their correlation with disease severity.

Psoriasis is a chronic, immune-mediated inflammatory dermatological condition that impacts around 0.2% to 4.8% of the worldwide population.

Interleukin (IL)-6 is a pleiotropic cytokine that regulates immunity, hematopoiesis, and inflammation. It is produced by keratinocytes, endothelial cells, fibroblasts, and immune cells like macrophages and dendritic cells. Increased IL-6 expression has been observed in psoriatic lesions, suggesting its involvement in disease pathogenesis

Inclusion Criteria:

• Age above 18 years.
• Both sexes.
• Patients clinically diagnosed with plaque psoriasis.

Exclusion Criteria:

• Patients who had received any treatment for psoriasis in the last three months.
• Patients with other types of psoriasis.
• Those currently receiving systemic treatment.
• Individuals with other inflammatory diseases.
• Pregnant or lactating women.
• Those using contraceptive pills.
• Patients with metabolic conditions like diabetes mellitus or thyroid disorders.

This cross-sectional work had been performed on 30 individuals with plaque psoriasis and 20 sex- and age-matched healthy controls.

The data will be available upon a reasonable request from the corresponding author after the end of study for one year.

After the end of study for one year.

The data will be available upon a reasonable request from the corresponding author.